Skip to main content
. 2020 Apr 9;59(13):1639–1642. doi: 10.2169/internalmedicine.4260-19

Figure 1.

Figure 1.

Computed tomography before pembrolizumab administration (A, B) and after four cycles of pembrolizumab administration (C, D). The primary lesion size in the left upper lobes and pulmonary metastases was significantly reduced.